Studies: Esbriet can improve life expectancies for idiopathic pulmonary fibrosis patients
ALEXANDRIA, Va. — Pirfenidone (Esbriet) can improve life expectancy compared with best supportive care and lower the risk of lung function decline for patients with idiopathic pulmonary fibrosis, an irreversible and unpredictable disease of unknown etiology that makes breathing difficult and causes permanent scarring damage to the lungs, according to two studies published in the March issue of the Journal of Managed Care & Specialty Pharmacy.
IPF is has no known cause and is fatal, often resulting in death in two to five years after diagnosis. It affects approximately 100,000 Americans and typically occurs in people older than 50. Historically, more men than women have been diagnosed with IPF. Common symptoms include a persistent dry cough; shortness of breath, sometimes even during normal daily activities; and “Velcro–like” crackles at the bases of the lungs, which a doctor can hear with a stethoscope. IPF is often initially misdiagnosed with other more common diseases such as asthma or chronic obstructive pulmonary disease. It can take months or even years to accurately diagnose IPF because the symptoms of IPF are very non-specific.
The first study, “Predicting Life Expectancy for Pirfenidone in Idiopathic Pulmonary Fibrosis,” revealed the Food and Drug Administration-approved drug, manufactured by Genenetech, can increase life expectancy in patients by 2.47 years compared to best supportive care. This study was funded by InterMune International AG, a wholly owned Roche subsidiary since 2014.
The second study, “Systematic Review and Network Meta-analysis of Idiopathic Pulmonary Fibrosis Treatments,” concluded pirfenidone may reduce the odds of experiencing a decline in percent predicted FVC of ≥10% compared with placebo in the first year of treatment. The results of the analysis also suggest that pirfenidone improves survival. FVC refers to Forced Vital Capacity, which is a measure of breath a person can exhale.
Northeast Ohio Medical University pioneers Transitions in Care with Ritzman Pharmacy
ROOTSTOWN, OHIO – The College of Pharmacy at Northeast Ohio Medical University on Friday launched the College’s first Transitions in Care program through its affiliate, Pharmacy Innovations, and in partnership with Ritzman Pharmacy at NEOMED and Summa Rehab Hospital.
“We hope to decrease re-admissions and increase compliance with patients taking their meds as prescribed,” stated Jeffrey Sanderson, medical director at Summa Rehab Hospital. “While it’s too early to project the long-run, we’ve already seen compliance – with patients getting their initial prescriptions filled – increase from an average 50% to 100% [for those introduced to the program].”
Services through the program, which began Jan. 5. 2017, include concierge service, medication education and discharge counseling – all at no additional charge to the patient.
The unique collaboration responds instantly to a number of critical concerns in health care today: medication adherence, access to quality health care and health literacy and re-admissions.
The process is fluid and begins as patients with varied medical needs are admitted to the Summa Rehab Hospital, a 60-bed inpatient acute medical rehabilitation hospital. Upon admission, patients are automatically enrolled in the Transitions in Care Program, but they may opt out if desired. Twenty-four hours prior to discharge, medication orders are sent to Ritzman Pharmacy at NEOMED for preparation. On the day of discharge the medications are delivered via courier to the Pharmacy Department at Summa Rehab. The Transitions in Care pharmacist then provides medication education, discharge counselling and discharge medications.
But it’s the direct interaction with pharmacists prior to discharge that’s key to increasing adherence, noted Charles Taylor, dean of the College of Pharmacy at NEOMED and president of Pharmacy Innovations. “Interprofessionally educated pharmacists can play a huge role as part of the care team. We need them to be recognized as providers of care.”
“It makes sense for pharmacist to play a role before discharge," agreed George Glatcz, COO Ritzman Pharmacy. "Usually a patient is sent home with a prescription, no medication education and no medication. It is no wonder that three out of four Americans do not take their medication as directed.”
Transitions in Care programs are on the increase. There are even a handful of residencies for Postgraduate Year Two (PGY2) pharmacists across the country. With health care facing an increased shortage of primary care physicians, medication adherence hovering around 50% and providers striving to reduce readmissions, patients, physicians and providers would all benefit from pharmacists as part of the care team, Glatcz noted.
Upsher-Smith inks deal to market and distribute three generic products
MAPLE GROVE, Minn. — Upsher-Smith Laboratories entered into an exclusive agreement with an emerging pharmaceutical company to market and distribute three generic products. These products will compete in markets with combined U.S. annual sales of nearly $200 million, according to IMS Health.
Under the terms of the agreement, the partner will develop, manufacture and supply the products exclusively for Upsher-Smith, which will market and distribute the products under its own label in the United States.
Financial terms related to the deal have not been disclosed. The name of the pharmaceutical company was not revealed in a news release.
"We are pleased to have entered into a partnership that will help Upsher-Smith build on its already strong presence in the U.S. generic marketplace," said Rusty Field, President, Upsher-Smith. "We look forward to creating more such partnerships with companies who share in our commitment to delivering quality, high-value generic products to patients."
Upsher-Smith Laboratories, Inc., founded in 1919, is a growing, fully integrated pharmaceutical company dedicated to its mission of delivering high-value, high-quality therapies and solutions which measurably improve individuals' lives.